Diagnostic value of PIVKA-II in detecting hepatocellular carcinoma

References

• 1 Theise ND, Chen C, Kew MK. Liver Cancer. In: World Cancer Report 2014. Stewart BW, Wild CP (Ed.). International Agency for Research on Cancer, Geneva, Switzerland, 403–412 (2014).
  Google Scholar
• 2 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(6), 1264–1273 (2012).
  MedlineGoogle Scholar
• 3 Lu FM, Zhuang H. Management of hepatitis B in China. Chin. Med. J. (Engl.) 122(1), 3–4 (2009).
  MedlineGoogle Scholar
• 4 Wei L, Hou JL. The guideline of prevention and treatment for hepatitis C: a 2015 update. Chin. J. Hepatol. 23(12), 906–923 (2015).
  Medline CASGoogle Scholar
• 5 Tanaka M, Katayama F, Kato H et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J. Epidemiol. 21(6), 401–416 (2011).
  MedlineGoogle Scholar
• 6 Zhang K, Song P, Gao J et al. Perspectives on a combined test of multi serum biomarkers in China: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Drug Discov. Ther. 8(3), 102–109 (2014).
  MedlineGoogle Scholar
• 7 Stravitz RT, Heuman DM, Chand N et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am. J. Med. 121(2), 119–126 (2008).
  MedlineGoogle Scholar
• 8 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020–1022 (2011).
  MedlineGoogle Scholar
• 9 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
  MedlineGoogle Scholar
• 10 Omata M, Lesmana LA, Tateishi R et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 4(2), 439–474 (2010).
  MedlineGoogle Scholar
• 11 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63(5), 844–855 (2014).
  Medline CASGoogle Scholar
• 12 Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J. Gastroenterol. Hepatol. 25(9), 1543–1549 (2010).
  Medline CASGoogle Scholar
• 13 Agopian VG, Harlander-Locke MP, Markovic D et al. Evaluation of patients with hepatocellular carcinomas that do not produce alpha-fetoprotein. JAMA Surg. 152(1), 55–64 (2017).
  MedlineGoogle Scholar
• 14 Nakao K, Ichikawa T. Recent topics on alpha-fetoprotein. Hepatol. Res. 43(8), 820–825 (2013).
  Medline CASGoogle Scholar
• 15 Beale G, Chattopadhyay D, Gray J et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 8(1), 1–8 (2008).
  MedlineGoogle Scholar
• 16 Kokudo N, Hasegawa K, Akahane M et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol. Res. 45(2), doi:10.1111/hepr.12464 (2015) (Epub ahead of print).
  Google Scholar
• 17 Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1), 110–118 (2009).
  Medline CASGoogle Scholar
• 18 Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 37(5), 1114–1121 (2003).
  Medline CASGoogle Scholar
• 19 Pote N, Cauchy F, Albuquerque M et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J. Hepatol. 62(4), 848–854 (2015).
  Medline CASGoogle Scholar
• 20 Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig. Dis. Sci. 52(3), 776–782 (2007).
  Medline CASGoogle Scholar
• 21 Hou JL, Lai W. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Chin. J. Hepatol. 23(12), 888–905 (2015).
  Medline CASGoogle Scholar
• 22 Song P, Gao J, Inagaki Y et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer 2(1), 31–39 (2013).
  Medline CASGoogle Scholar
• 23 Song P, Feng X, Zhang K et al. Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg. Nutr. 2(4), 227–231 (2013).
  MedlineGoogle Scholar
• 24 Gentilini P, Laffi G, Villa G et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am. J. Gastroenterol. 92(1), 66–72 (1997).
  Medline CASGoogle Scholar
• 25 Nakamura S, Nouso K, Sakaguchi K et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am. J. Gastroenterol. 101(9), 2038–2043 (2006).
  Medline CASGoogle Scholar
• 26 Ette AI, Ndububa DA, Adekanle O, Ekrikpo UE. Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study. BMC Gastroenterol. 15(1), 113 (2015).
  MedlineGoogle Scholar
• 27 Inagaki Y, Xu HL, Hasegawa K et al. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis. J. Dig. Dis. 12(6), 481–488 (2011).
  Medline CASGoogle Scholar
• 28 Ji J, Wang H, Li Y et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multicentre study. PLoS ONE 11(4), e0153227 (2016).
  MedlineGoogle Scholar
• 29 Durazo FA, Blatt LM, Corey WG et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 23(10), 1541–1548 (2008).
  Medline CASGoogle Scholar
• 30 Choi J, Park Y, Kim JH, Kim HS. Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma. Clin. Biochem. 44(17–18), 1464–1468 (2011).
  Medline CASGoogle Scholar
• 31 Feng X, Song P, Bie P et al. Des-gamma-carboxyprothrombin plasma level in diagnosis of hepatocellular carcinoma in a Chinese population undergoing surgery. Med. Sci. Monit. 22, 1663–1672 (2016).
  Medline CASGoogle Scholar
• 32 Song P, Feng X, Inagaki Y et al. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: a multi-center case-controlled study of 1153 subjects. Biosci. Trends 8(5), 266–273 (2014).
  Medline CASGoogle Scholar
• 33 Okuda H, Nakanishi T, Takatsu K et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 88(3), 544–549 (2000).
  Medline CASGoogle Scholar
• 34 Ohhira M, Saito H, Suzuki Y et al. A variant of des-gamma-carboxy prothrombin was increased in alcoholic liver disease without hepatocellular carcinoma. Alcohol. Clin. Exp. Res. 25(Suppl. 6), S46–S50 (2001).
  MedlineGoogle Scholar
• 35 Cui R, Wang B, Ding H, Shen H, Li Y, Chen X. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Chin. Med. J. (Engl.) 115(1), 42–45 (2002).
  Medline CASGoogle Scholar
• 36 Cui R, He J, Zhang F et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br. J. Cancer 88(12), 1878–1882 (2003).
  Medline CASGoogle Scholar
• 37 Choi JY, Jung SW, Kim HY et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J. Gastroenterol. 19(3), 339–346 (2013).
  Medline CASGoogle Scholar